- Home
- PHAT vs NVRI Comparison
PHAT vs NVRI Comparison
Compare PHAT & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- NVRI
- Stock Information
- Founded
- PHAT 2018
- NVRI 1853
- Country
- PHAT United States
- NVRI United States
- Employees
- PHAT N/A
- NVRI N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- NVRI Diversified Commercial Services
- Sector
- PHAT Health Care
- NVRI Miscellaneous
- Exchange
- PHAT Nasdaq
- NVRI Nasdaq
- Market Cap
- PHAT 942.6M
- NVRI 996.0M
- IPO Year
- PHAT 2019
- NVRI N/A
- Fundamental
- Price
- PHAT $14.85
- NVRI $13.43
- Analyst Decision
- PHAT Strong Buy
- NVRI
- Analyst Count
- PHAT 5
- NVRI 0
- Target Price
- PHAT $17.60
- NVRI N/A
- AVG Volume (30 Days)
- PHAT 983.2K
- NVRI 1.4M
- Earning Date
- PHAT 10-30-2025
- NVRI 11-10-2025
- Dividend Yield
- PHAT N/A
- NVRI N/A
- EPS Growth
- PHAT N/A
- NVRI N/A
- EPS
- PHAT N/A
- NVRI N/A
- Revenue
- PHAT $147,190,000.00
- NVRI $2,244,061,000.00
- Revenue This Year
- PHAT $218.38
- NVRI N/A
- Revenue Next Year
- PHAT $87.14
- NVRI $3.72
- P/E Ratio
- PHAT N/A
- NVRI N/A
- Revenue Growth
- PHAT 460.30
- NVRI N/A
- 52 Week Low
- PHAT $2.21
- NVRI $4.72
- 52 Week High
- PHAT $16.08
- NVRI $13.86
- Technical
- Relative Strength Index (RSI)
- PHAT 64.62
- NVRI 60.71
- Support Level
- PHAT $14.12
- NVRI $12.87
- Resistance Level
- PHAT $15.28
- NVRI $13.69
- Average True Range (ATR)
- PHAT 0.93
- NVRI 0.66
- MACD
- PHAT 0.07
- NVRI 0.05
- Stochastic Oscillator
- PHAT 82.58
- NVRI 82.47
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.